X0508 4 2024-03-20 0001205922 VACCINEX, INC. VCNX 0001747769 Smith Ernest S. C/O VACCINEX, INC. 1895 MOUNT HOPE AVENUE ROCHESTER NY 14620 0 1 0 0 SVP, Research & CSO 0 Common Stock 39 D Stock Option (Right to Buy) 1491.0 2025-12-22 Common Stock 193 193 D Stock Option (Right to Buy) 1491.0 2025-12-23 Common Stock 24 24 D Stock Option (Right to Buy) 819.0 2029-03-14 Common Stock 38 38 D Stock Option (Right to Buy) 1274.7 2030-02-24 Common Stock 38 38 D Stock Option (Right to Buy) 615.3 2031-04-02 Common Stock 47 47 D Stock Option (Right to Buy) 270.9 2032-04-01 Common Stock 95 95 D Stock Option (Right to Buy) 83.9 2033-03-30 Common Stock 190 190 D Stock Option (Right to Buy) 8.32 2024-03-20 4 A 0 1341 0 A 2034-03-20 Common Stock 1341 1341 D Exercisable in full as of the date of this report. This option vests one-fourth on each of the first four anniversaries of the April 2, 2021 grant date, except as otherwise provided in the award notice. This option vests one-fourth on each of the first four anniversaries of the April 1, 2022 grant date, except as otherwise provided in the award notice. This option vests one-fourth on each of the first four anniversaries of the March 31, 2023 grant date, except as otherwise provided in the award notice. This option was granted under the Company's 2018 Omnibus Incentive Plan in a transaction exempt under Rule 16b-3 and, except as otherwise provided in the award notice, vests one-fourth on each of the first four anniversaries of the March 20, 2024 grant date. All figures in this Form 4 reflect the Issuer's 1-for-15 reverse stock split effected on September 25, 2023 and 1-for-14 reverse stock split effected on February 19, 2024. /s/ Maurice Zauderer, Attorney-in-Fact for Ernest S. Smith 2024-03-22